Key Drivers
- Cash Rich
- No Revenue
- High Burn
AIAI Summary
TYRA should be viewed now as a well-funded, late-stage biotech with runway into 2H 2028 and multiple shots on goal, but the investment case is still almost entirely binary on dabogratinib clinical execution—meaning the stock has downside protection from the balance sheet, yet no durable upside unless upcoming data break through resistance and de-risk the pipeline.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Rich
- •No Revenue
- •High Burn
TYRA has a strong, low-debt balance sheet with ample liquidity, but no revenue, ongoing losses, and continued cash burn make its 5.55x book valuation look stretched.
Price Behavior
Key Price Behavior Insights:
- •Rebound Strength
- •Near Resistance
- •Support Watch
TYRA's rebound from $32.90 to $37.04 has improved near-term momentum, but it still needs a convincing close above $37.59 to confirm a breakout above resistance.
Sharp rebound from $32.90 to $37.04 after a short-term decline
Sentiment & News
Key News Insights:
- •Analyst Support
- •Pipeline Readouts
- •Cash Runway
Tyra Biosciences is drawing bullish analyst support while advancing its dabogratinib pipeline, with key clinical readouts due in 2026-2027 and a cash runway into 2H 2028.
The update is positive for TYRA, strengthening confidence in clinical execution and lowering near-term financing concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings